MetLife Investment Management’s Audacy, Inc. AUD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-52,952
Closed -$153K 2931
2022
Q1
$153K Buy
52,952
+40,213
+316% +$106K ﹤0.01% 2508
2021
Q4
$32.7K Sell
12,739
-30,016
-70% -$92.4K ﹤0.01% 2476
2021
Q3
$157K Buy
42,755
+24,037
+128% +$84.2K ﹤0.01% 2233
2021
Q2
$80.7K Sell
18,718
-26,572
-59% -$122K ﹤0.01% 2411
2021
Q1
$238K Buy
+45,290
New +$220K ﹤0.01% 1963
2020
Q2
Sell
-57,852
Closed -$98.9K 2374
2020
Q1
$98.9K Buy
57,852
+19,882
+52% +$72.2K ﹤0.01% 2085
2019
Q4
$176K Sell
37,970
-19,615
-34% -$82K ﹤0.01% 2046
2019
Q3
$192K Buy
57,585
+75
+0.1% +$336 ﹤0.01% 1972
2019
Q2
$334K Hold
57,510
﹤0.01% 1731
2019
Q1
$302K Hold
57,510
﹤0.01% 1746
2018
Q4
$328K Buy
57,510
+11,344
+25% +$75.5K ﹤0.01% 1621
2018
Q3
$365K Sell
46,166
-13,614
-23% -$105K ﹤0.01% 1733
2018
Q2
$451K Buy
59,780
+10,507
+21% +$89.1K 0.01% 1465
2018
Q1
$475K Sell
49,273
-10,593
-18% -$110K 0.01% 1401
2017
Q4
$647K Buy
+59,866
New +$681K 0.01% 1251

Other funds holding AUD

MetLife Investment Management's AUD Position: Q2 2022 in Review

MetLife Investment Management sold out of Audacy, Inc. (AUD) in Q2 2022, closing a stake of 52,952 shares — an estimated $153K sold.

MetLife Investment Management first reported a position in AUD in Q4 2017 and held it in 15 quarters. The position peaked at $647K in Q4 2017. 131 funds tracked by Wall St. Rank hold AUD as of Q2 2022.

  • MetLife Investment Management reported no remaining Audacy, Inc. position as of Q2 2022 after selling out during the quarter.
  • MetLife Investment Management sold 52,952 Audacy, Inc. shares in Q2 2022, an estimated $153K.
  • MetLife Investment Management first reported a position in Audacy, Inc. in Q4 2017 and held it in 15 quarters.
  • MetLife Investment Management's Audacy, Inc. position peaked at $647K in Q4 2017.
  • 131 funds tracked by Wall St. Rank held Audacy, Inc. as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.